Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Cortical Disarray Measurement (CDM®) as a tool to diagnose mild cognitive impairment (MCI) due to Alzheimer’s disease

  • Mental health HTA and economic evaluations

Research aim

Evaluation of Cortical Disarray Measurement (CDM®) as a novel tool to identify and predict disease progression among patients presenting with mild cognitive impairment due to Alzheimer’s disease.

A model‑based cost‑effectiveness analysis will be developed. Data to inform the model will be obtained from patient advisory groups, clinical experts, cohort data collected during this study and the literature.

Funders: NIHR i4i PDA

Chief Investigator

Dr Steven Chance, CEO, Co-Founder & Board member, Oxford Brain Diagnostics

Dr Steven Chance

Oxford Brain Diagnostics

Selected publications

Systematic review of health economic models for assessment and diagnosis of dementia

Journal article

Kwon J. et al, (2025), Alzheimer's & Dementia: Behavior & Socioeconomics of Aging, 1